Defining recompensation of alcohol‐related liver disease: A step beyond decompensated cirrhosis

医学 酒精性肝病 肝硬化 肝病 胃肠病学 内科学 重症监护医学
作者
Jordi Gratacós‐Ginès,Elisa Pose
出处
期刊:Liver International [Wiley]
卷期号:43 (10): 2060-2061 被引量:1
标识
DOI:10.1111/liv.15690
摘要

Alcohol is the main cause of advanced liver disease in the Western world, and it is associated with the highest economic and social impact.1 Characteristically, the disease is underdiagnosed at early stages, and still nowadays, most patients are diagnosed when presenting with the first decompensation of cirrhosis.2 Classical studies on the natural history of alcohol-related cirrhosis were focused on investigating factors associated with liver disease progression or death, considering the disease irreversible in nature. However, some studies performed decades ago in small cohorts already described the clinical phenomenon of improvement of liver function and resolution of decompensations in patients with alcohol-related cirrhosis and alcohol-associated hepatitis.3, 4 More recent studies shed some light on this phenomenon reporting the observation of liver function improvement and resolution of decompensations in patients with alcohol-related cirrhosis awaiting liver transplantation, leading to the removal from the waiting list.5-7 In these studies, albumin levels, indirect biomarkers of portal hypertension such as platelet count and time of alcohol abstinence prior to inclusion in the waiting list were found to be associated with clinical improvement. These studies were useful to describe the clinical relevance of the phenomenon of recompensation, but they also left unanswered questions derived from the fact that they were focused on a very specific population of candidates for liver transplantation. Until a few years ago, the phenomenon of cirrhosis recompensation has been mostly investigated in patients with hepatitis C who experienced a resolution of cirrhosis decompensations after the cure of the virus.8 As a result of the evidence derived from these studies, the Baveno consensus recently provided a definition of recompensation in patients with decompensated cirrhosis of different aetiologies, including clinical criteria, such as controlled ascites without diuretic treatment and absence of hepatic encephalopathy or gastrointestinal bleeding in the prior year in a patient with sustained alcohol abstinence.9 These criteria are very valuable as they provide a homogeneous definition of the phenomenon of recompensation to be used in further studies; however, as these criteria were defined by expert consensus and not specifically created for patients with alcohol-related cirrhosis, there is room for further refinements when more evidence on the natural history of the disease is available. In that regard, the criteria established in the Baveno VII consensus include total alcohol abstinence for establishing the diagnosis of recompensation; however, there is growing evidence that in decompensated patients, liver function may improve after reducing the amount of alcohol consumed without achieving total abstinence, the so-called 'harm reduction' hypothesis.10 Future revisions of Baveno criteria will probably need to consider these specific characteristics of the natural history of alcohol-related cirrhosis. In this context, the study by Hofer and colleagues in Liver International is of great interest,11 as it defines the phenomenon of recompensation in a large cohort of patients with alcohol-related decompensated cirrhosis. The investigators included a well-characterized cohort of patients with baseline portal pressure gradient measurement. The authors report a prevalence of recompensation of 18% after a median follow-up of 2 years, which is significantly higher than that previously reported in studies in liver transplant candidates. However, it should be noted that patients included in this analysis had a less severe liver function impairment, with a median MELD score of 14 points, and most patients being Child-Pugh A or B at inclusion. The authors also show that the prognosis of patients that experience recompensation is markedly better than that of patients who remain decompensated, both in the mid and long term. Also, the study nicely points out that Child-Pugh score and albumin levels, body mass index, mean arterial pressure and portal pressure gradient may help predicting the occurrence of recompensation in the setting of alcohol-related cirrhosis. In this regard, one of the main strengths of the study is that it includes a baseline measurement of portal pressure gradient by hepatic hemodynamics. The association between the degree of portal pressure and the risk of liver disease progression, decompensation and death has been widely investigated in cirrhosis.12 However, the association between portal pressure and the probability of resolution of complications or regression of liver disease has been scarcely investigated, only in studies including a small number of patients. To our knowledge, this is the first time that portal pressure gradient has been described as a predictor of recompensation in a large cohort of patients with alcohol-related decompensated cirrhosis, which is a notable contribution to the field. Interestingly, parameters of liver function such as Child-Pugh score and albumin levels, both previously associated with recompensation in patients listed for liver transplantation, were found as predictive factors of recompensation in this study. These findings support the idea that there is probably a window of opportunity for recompensation in patients with cirrhosis and that it is highly unlikely of happening when progressing beyond a certain threshold of liver function impairment. Finally, an interesting finding is the association found between obesity and the probability of recompensation. No robust information is available on the effect that metabolic risk factors may have on the prognosis of alcohol-related liver disease. Two decades ago, Naveau et al. described obesity as a risk factor for cirrhosis and alcohol-associated hepatitis13; however, no further studies have been published in recent years exploring the effect of metabolic risk factors in advanced stages of alcohol-related cirrhosis. The current study provides new evidence that metabolic risk factors, particularly obesity, have deleterious effects in patients with alcohol-related decompensated cirrhosis, preventing recompensation in these patients. More studies are needed to further investigate the interaction between alcohol and metabolic syndrome in patients with liver disease. This study has some drawbacks, derived from the retrospective nature of the design: the lack of detailed information on alcohological follow-up, and the exclusion of patients with alcohol-associated hepatitis and acute-on-chronic liver failure. Although the probability of recompensation may be relatively low in such advanced stages of the disease, identifying the factors associated with the resolution of complications of cirrhosis may be of high interest in this population, as it may be crucial for the management of these patients, especially considering the widely extended indication for early liver transplantation in patients with alcohol-associated hepatitis. Another potential shortcoming of the study could be derived from the use of the Baveno VII definition of recompensation in the context of alcohol-related liver disease, especially regarding the criteria of sustained alcohol abstinence that may be too restrictive and underestimate the actual prevalence of recompensation in alcohol-related liver disease. In summary, this study represents one more step in the knowledge of the natural history of alcohol-related cirrhosis once clinical decompensations occur. New studies investigating biomarkers of recompensation will be needed in order to improve the risk assessment in patients with alcohol-related liver disease and to gain knowledge on possible therapeutic targets to guide new experimental therapies in this population. While achieving alcohol abstinence will still be one of the main goals, a treatment paradigm shift from preventing progression to favouring regression might be a better strategy moving forward. The authors do not have any disclosures to report. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
打打应助pan采纳,获得10
1秒前
1秒前
Hello应助coolboy111采纳,获得10
2秒前
happy的语墨完成签到 ,获得积分10
3秒前
如何呢完成签到,获得积分10
5秒前
stupid发布了新的文献求助10
5秒前
5秒前
6秒前
如何呢发布了新的文献求助10
7秒前
8秒前
那就求个好运应助123采纳,获得20
8秒前
9秒前
000完成签到,获得积分10
9秒前
Pursue完成签到,获得积分10
9秒前
10秒前
10秒前
OK给多开心奶粉的求助进行了留言
11秒前
11秒前
斯文败类应助清脆的映冬采纳,获得10
11秒前
12秒前
KYTYYDS发布了新的文献求助10
12秒前
搜集达人应助stupid采纳,获得10
13秒前
牢大发布了新的文献求助10
14秒前
荔枝花发布了新的文献求助10
15秒前
默默zzz完成签到 ,获得积分10
15秒前
三维码发布了新的文献求助10
16秒前
16秒前
Owen应助时衍采纳,获得10
16秒前
wulala发布了新的文献求助10
16秒前
有米饭没完成签到 ,获得积分10
17秒前
alworld发布了新的文献求助10
17秒前
端庄的含巧完成签到,获得积分20
19秒前
19秒前
20秒前
学术孤儿应助jaci采纳,获得10
20秒前
Nole应助jaci采纳,获得10
20秒前
大模型应助可靠冰姬采纳,获得10
21秒前
22秒前
张欢馨应助感谢大佬打赏采纳,获得10
22秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 5000
Pediatric Dermoscopy Trichoscopy & Onychoscopy 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Additive Manufacturing Design and Applications (ASM Handbook, Volume 24A) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7570300
求助须知:如何正确求助?哪些是违规求助? 9150243
关于积分的说明 19569776
捐赠科研通 7155812
什么是DOI,文献DOI怎么找? 3263839
关于科研通互助平台的介绍 2429260
邀请新用户注册赠送积分活动 2253907